Literature DB >> 10969692

Mechanisms responsible for cell volume regulation during hyperkalemic cardioplegic arrest.

X Sun1, C T Ducko, E M Hoenicke, K Reigle, R J Damiano.   

Abstract

BACKGROUND: Cardioplegia has been shown to induce significant cell swelling. This study tested the hypothesis that (1) the [K+][Cl-] product of the cardioplegia solution is the main determinant of myocyte swelling, and (2) reperfusion myocyte shrinkage results from a rectifying Cl- conductance.
METHODS: Rabbit ventricular myocytes were superfused with 37 degrees C Krebs-Henseleit solution for 10 minutes. Then cells underwent 20 minutes of superfusion with standard St. Thomas' solution ([K+][Cl-] product = 2566 mmol/L2) and two solutions with lower [K+][Cl-] product (1500 and 700 mmol/L2) at 9 degrees C. Cells were then resuperfused with 37 degrees C Krebs-Henseleit solution for 30 minutes. Cell volume was measured by videomicroscopy.
RESULTS: Cells superfused with St. Thomas' having [K+][Cl-] products of 2,566, 1,500, and 700 mmol/L2 swelled by 9.18%+/-3.57%, 5.51%+/-1.08%, and 1.49%+/-1.56%, respectively. Reexposure to Krebs-Henseleit solution caused these cells to shrink by 5.79%+/-1.41%, 8.72% +/-3.68%, and 13.46%+/-5.60%, respectively. This shrinkage was blocked by Cl- channel blockers given at the onset of superfusion.
CONCLUSIONS: Lowering the [K+][Cl-] product of St. Thomas' solution attenuated myocyte edema. Myocyte shrinkage during reexposure to Krebs-Henseleit solution resulted from the volume-activated Cl- channel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969692     DOI: 10.1016/s0003-4975(00)01403-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  St. Thomas Modified Cardioplegia Effects on Myoblasts' Viability and Morphology.

Authors:  Rafał Nowicki; Katarzyna Bieżuńska-Kusiak; Julita Kulbacka; Anna Choromanska; Małgorzata Daczewska; Stanisław Potoczek; Maciej Rachwalik; Jolanta Saczko
Journal:  Medicina (Kaunas)       Date:  2022-02-13       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.